2743 | Humans |
2508 | Influenza, Human |
1160 | Influenza A Virus, H1N1 Subtype |
1087 | Disease Outbreaks |
904 | Pandemics |
829 | Female |
783 | Influenza Vaccines |
710 | Animals |
706 | Adult |
704 | Male |
559 | Middle Aged |
497 | Adolescent |
430 | Child |
414 | Young Adult |
407 | Aged |
391 | United States |
376 | Antiviral Agents |
354 | Influenza A Virus, H5N1 Subtype |
338 | Child, Preschool |
330 | History, 20th Century |
276 | Infant |
275 | Influenza A virus |
260 | Vaccination |
243 | Disaster Planning |
224 | Influenza in Birds |
209 | Orthomyxoviridae Infections |
190 | Antibodies, Viral |
183 | Aged, 80 and over |
171 | Birds |
166 | Hemagglutinin Glycoproteins, Influenza Virus |
165 | Infant, Newborn |
164 | Global Health |
162 | Mice |
160 | Communicable Disease Control |
159 | Public Health |
152 | Seasons |
148 | Risk Factors |
139 | Population Surveillance |
138 | Time Factors |
129 | Hospitalization |
125 | Neuraminidase |
117 | Influenza Pandemic, 1918-1919 |
115 | Oseltamivir |
110 | Surveys and Questionnaires |
107 | Orthomyxoviridae |
103 | Pregnancy |
102 | Mice, Inbred BALB C |
102 | Incidence |
95 | World Health Organization |
95 | Models, Theoretical |
93 | Health Knowledge, Attitudes, Practice |
93 | Cross-Sectional Studies |
92 | Retrospective Studies |
91 | Age Factors |
88 | Models, Biological |
87 | Risk Assessment |
87 | China |
86 | Influenza A Virus, H3N2 Subtype |
84 | Age Distribution |
83 | Health Planning |
79 | Swine |
78 | Molecular Sequence Data |
78 | Europe |
77 | Models, Statistical |
77 | Computer Simulation |
76 | Cell Line |
75 | Virulence |
73 | Health Policy |
73 | Australia |
72 | Attitude of Health Personnel |
71 | Viral Proteins |
71 | Phylogeny |
71 | Infection Control |
70 | Adjuvants, Immunologic |
69 | Virus Replication |
69 | Hemagglutination Inhibition Tests |
67 | United Kingdom |
67 | RNA, Viral |
66 | Zoonoses |
65 | Severity of Illness Index |
65 | Lung |
65 | Drug Resistance, Viral |
63 | Health Personnel |
62 | Poultry |
60 | Schools |
59 | Disease Models, Animal |
58 | Treatment Outcome |
58 | Reverse Transcriptase Polymerase Chain Reaction |
58 | France |
57 | Dogs |
57 | Antigens, Viral |
55 | Pregnancy Complications, Infectious |
54 | Reassortant Viruses |
54 | Mutation |
53 | Military Personnel |
53 | Mass Vaccination |
53 | Intensive Care Units |
53 | History, 21st Century |
51 | Cohort Studies |
50 | Respiratory Tract Infections |
50 | Ferrets |
49 | Travel |
49 | Survival Analysis |
48 | Prospective Studies |
47 | Triage |
47 | Quarantine |
47 | Prevalence |
47 | Japan |
46 | Hong Kong |
46 | Germany |
46 | Canada |
46 | Amino Acid Sequence |
45 | Vaccines, Inactivated |
45 | Sentinel Surveillance |
45 | Disease Transmission, Infectious |
44 | Mexico |
43 | Patient Acceptance of Health Care |
43 | Chickens |
43 | Antibodies, Neutralizing |
42 | Spain |
42 | Sensitivity and Specificity |
40 | Public Health Administration |
40 | Pneumonia, Viral |
40 | Neutralization Tests |
40 | Emergency Service, Hospital |
39 | Public Health Practice |
39 | New Zealand |
39 | Immunization Programs |
39 | Cross Reactions |
38 | Influenza A Virus, H7N9 Subtype |
38 | Forecasting |
37 | Socioeconomic Factors |
37 | England |
37 | Communicable Diseases |
36 | Pneumonia |
36 | Evolution, Molecular |
36 | Epidemics |
35 | Risk |
35 | Data Collection |
34 | Vaccines, Synthetic |
34 | Severe Acute Respiratory Syndrome |
34 | Italy |
34 | Influenza B virus |
34 | Enzyme Inhibitors |
34 | Cost-Benefit Analysis |
34 | Clinical Trials as Topic |
33 | Viral Matrix Proteins |
33 | Ontario |
32 | Vaccines, Attenuated |
32 | Species Specificity |
32 | Communicable Diseases, Emerging |
31 | Pneumonia, Bacterial |
31 | Mortality |
31 | India |
31 | Delivery of Health Care |
31 | Critical Care |
31 | Absenteeism |
30 | Practice Guidelines as Topic |
30 | Netherlands |
30 | Communication |
30 | Centers for Disease Control and Prevention, U.S. |
29 | Viral Load |
29 | Urban Population |
29 | Genome, Viral |
29 | Coinfection |
28 | World War I |
28 | Swine Diseases |
28 | Sequence Analysis, DNA |
28 | Health Services Accessibility |
28 | Health Care Surveys |
28 | Decision Making |
28 | Civil Defense |
27 | Receptors, Virus |
27 | Mice, Inbred C57BL |
27 | Interviews as Topic |
27 | Cross Infection |
27 | Asia |
26 | Resource Allocation |
26 | Poultry Diseases |
26 | Personnel, Hospital |
26 | Models, Molecular |
26 | Madin Darby Canine Kidney Cells |
26 | International Cooperation |
26 | Hospitals |
26 | History, 19th Century |
26 | Health Planning Guidelines |
25 | Real-Time Polymerase Chain Reaction |
25 | Masks |
25 | Logistic Models |
25 | Internet |
25 | Hemagglutinins, Viral |
25 | Health Care Rationing |
25 | Cytokines |
25 | Anti-Bacterial Agents |
25 | Algorithms |
24 | Health Behavior |
24 | Genetic Variation |
24 | Family Characteristics |
24 | Disease Reservoirs |
24 | Comorbidity |
24 | Cause of Death |
24 | Amino Acid Substitution |
23 | Vaccines, DNA |
23 | Registries |
23 | Qualitative Research |
23 | Immunization |
23 | Cross Protection |
23 | Base Sequence |
22 | Respiration, Artificial |
22 | Hemagglutinins |
22 | Health Services Needs and Demand |
22 | Geography |
22 | Databases, Factual |
22 | Community-Acquired Infections |
21 | Singapore |
21 | Sex Factors |
21 | Sequence Alignment |
21 | Respiratory Distress Syndrome, Adult |
21 | Protein Binding |
21 | Polymerase Chain Reaction |
21 | Influenza A Virus, H9N2 Subtype |
21 | Immunoglobulin G |
21 | Host-Pathogen Interactions |
21 | Health Resources |
21 | Emergencies |
20 | Workforce |
20 | Regression Analysis |
20 | Primary Health Care |
20 | Patient Isolation |
20 | Extracorporeal Membrane Oxygenation |
20 | Cost of Illness |
19 | Respiratory Tract Diseases |
19 | Reproducibility of Results |
19 | Protein Conformation |
19 | Odds Ratio |
19 | Occupational Exposure |
19 | Hand Disinfection |
19 | Epitopes |
19 | Chick Embryo |
19 | Bioterrorism |
19 | Antibodies, Monoclonal |
18 | Vulnerable Populations |
18 | Virus Shedding |
18 | Taiwan |
18 | Sweden |
18 | Survival Rate |
18 | Seroepidemiologic Studies |
18 | Respiratory Protective Devices |
18 | Public Opinion |
18 | Pilot Projects |
18 | Norway |
18 | Mass Casualty Incidents |
18 | Infectious Disease Transmission, Patient-to-Professional |
18 | Health Promotion |
18 | European Union |
18 | Ducks |
18 | Developing Countries |
18 | Case-Control Studies |
17 | Zanamivir |
17 | Vero Cells |
17 | Squalene |
17 | Rural Population |
17 | Primary Prevention |
17 | Information Dissemination |
17 | Inflammation |
17 | Epidemiological Monitoring |
17 | Disease Notification |
17 | Critical Illness |
17 | Chlorocebus aethiops |
17 | CD8-Positive T-Lymphocytes |
17 | Brazil |
17 | Attitude to Health |
16 | Vaccines |
16 | T-Lymphocytes |
16 | Polysorbates |
16 | Pneumococcal Vaccines |
16 | Physicians |
16 | Needs Assessment |
16 | Internationality |
16 | Influenza A Virus, H2N2 Subtype |
16 | Hygiene |
16 | Health Education |
16 | Genes, Viral |
16 | Family Practice |
16 | Emergency Medical Services |
16 | Computational Biology |
16 | Amantadine |
15 | Viral Vaccines |
15 | Thailand |
15 | Surge Capacity |
15 | Students |
15 | Sex Distribution |
15 | Risk Management |
15 | Residence Characteristics |
15 | Recombination, Genetic |
15 | Probability |
15 | Occupational Health |
15 | Mutation, Missense |
15 | Models, Economic |
15 | Israel |
15 | Immunity, Cellular |
15 | Genetic Vectors |
15 | Follow-Up Studies |
15 | Enzyme-Linked Immunosorbent Assay |
15 | Drug Design |
15 | Crystallography, X-Ray |
15 | CD4-Positive T-Lymphocytes |
15 | Binding Sites |
15 | Basic Reproduction Number |
15 | Bacterial Infections |
15 | Acetamides |
14 | Virus Attachment |
14 | Ventilators, Mechanical |
14 | Universities |
14 | Technology, Pharmaceutical |
14 | Switzerland |
14 | Respiratory System |
14 | Program Evaluation |
14 | Nasopharynx |
14 | Length of Stay |
14 | Immunization, Secondary |
14 | Epithelial Cells |
14 | Drug Discovery |
14 | Disease Susceptibility |
14 | Cluster Analysis |
14 | Cities |
14 | Cells, Cultured |
14 | Antigenic Variation |
13 | Virus Cultivation |
13 | Virulence Factors |
13 | Virology |
13 | Viral Nonstructural Proteins |
13 | Streptococcus pneumoniae |
13 | RNA Replicase |
13 | Protein Structure, Tertiary |
13 | Practice Patterns, Physicians' |
13 | Pneumonia, Pneumococcal |
13 | Patient Admission |
13 | Oligonucleotide Array Sequence Analysis |
13 | Nurses |
13 | National Health Programs |
13 | Models, Immunological |
13 | Mass Media |
13 | Guidelines as Topic |
13 | Gene Expression Profiling |
13 | Focus Groups |
13 | Drug Industry |
13 | Confidence Intervals |
13 | Biomedical Research |
13 | Administration, Intranasal |
12 | Stochastic Processes |
12 | Prenatal Exposure Delayed Effects |
12 | Physician's Role |
12 | Patient Compliance |
12 | North America |
12 | Narcolepsy |
12 | Multivariate Analysis |
12 | Monte Carlo Method |
12 | Immunization Schedule |
12 | Health Priorities |
12 | Guideline Adherence |
12 | Genetic Drift |
12 | Fever |
12 | Ethics, Medical |
12 | Dose-Response Relationship, Immunologic |
12 | DNA, Viral |
12 | Coronavirus Infections |
12 | Cooperative Behavior |
12 | Community Health Services |
12 | Biomarkers |
12 | Biological Evolution |
12 | Antibody Formation |
11 | Water Pollutants, Chemical |
11 | Wales |
11 | Vaccines, Virus-Like Particle |
11 | Trust |
11 | Texas |
11 | Spatio-Temporal Analysis |
11 | Security Measures |
11 | Recombinant Proteins |
11 | Quality-Adjusted Life Years |
11 | Public Policy |
11 | Predictive Value of Tests |
11 | Obesity |
11 | Nurse's Role |
11 | New York City |
11 | Moral Obligations |
11 | Longitudinal Studies |
11 | Immunologic Memory |
11 | Immunity, Humoral |
11 | Hospitals, University |
11 | Health Surveys |
11 | Health Plan Implementation |
11 | HEK293 Cells |
11 | Guanidines |
11 | Genotype |
11 | Drug Combinations |
11 | Double-Blind Method |
11 | Dose-Response Relationship, Drug |
11 | DNA Primers |
11 | Conserved Sequence |
11 | Commerce |
11 | Chile |
11 | Asthma |
11 | Africa |
11 | Aerosols |
10 | Warfare |
10 | Virus Diseases |
10 | Victoria |
10 | Urban Health |
10 | Social Class |
10 | Sialic Acids |
10 | Russia |
10 | Proportional Hazards Models |
10 | Program Development |
10 | Prognosis |
10 | Pregnancy Outcome |
10 | Poverty |
10 | Pneumococcal Infections |
10 | Perception |
10 | New South Wales |
10 | Molecular Epidemiology |
10 | Military Medicine |
10 | Laboratories |
10 | Interferon-gamma |
10 | Hospitals, Pediatric |
10 | Health Care Costs |
10 | Guinea Pigs |
10 | Gene Expression |
10 | Fear |
10 | Epidemiologic Methods |
10 | Employment |
10 | Clinical Laboratory Techniques |
10 | Clinical Competence |
10 | California |
10 | Ambulatory Care Facilities |
10 | Adenoviridae |
9 | Viruses |
9 | Respiratory Mucosa |
9 | Republic of Korea |
9 | Regional Health Planning |
9 | Randomized Controlled Trials as Topic |
9 | RNA-Binding Proteins |
9 | Professional Competence |
9 | Physicians, Family |
9 | Peptides |
9 | Organizational Case Studies |
9 | Motivation |
9 | Microbial Sensitivity Tests |
9 | Lymphocyte Activation |
9 | Influenza A Virus, H5N2 Subtype |
9 | Immunologic Factors |
9 | Immunization, Passive |
9 | Immunity, Mucosal |
9 | Immunity, Innate |
9 | Hydroxymethylglutaryl-CoA Reductase Inhibitors |
9 | Healthcare Disparities |
9 | Health Status |
9 | Guillain-Barre Syndrome |
9 | Greece |
9 | Evidence-Based Medicine |
9 | Drug-Related Side Effects and Adverse Reactions |
9 | Drug Therapy, Combination |
9 | Death Certificates |
9 | Cyclopentanes |
9 | Cough |
9 | Cell Culture Techniques |
9 | Betacoronavirus |
9 | Asia, Southeastern |
8 | Workplace |
8 | Volunteers |
8 | Virus Internalization |
8 | Virion |
8 | Vaccines, Subunit |
8 | Turkey |
8 | Tuberculosis |
8 | Transportation |
8 | Structure-Activity Relationship |
8 | Software |
8 | Social Justice |
8 | Signal Transduction |
8 | Self Report |
8 | School Health Services |
8 | Safety Management |
8 | Rural Health |
8 | Respiratory Insufficiency |
8 | Recombinant Fusion Proteins |
8 | RNA, Messenger |
8 | Public Health Surveillance |
8 | Preventive Health Services |
8 | Population Dynamics |
8 | Polysaccharides |
8 | Poland |
8 | Patient Selection |
8 | Patient Education as Topic |
8 | Parents |
8 | Pacific Islands |
8 | Outpatients |
8 | Occupational Diseases |
8 | North Carolina |